I see the recent sell-off as an overreaction to the unfortunate patient death. Given that more than 800 patients have been treated with Elevidys and t...
Read
More
I see the recent sell-off as an overreaction to the unfortunate patient death. Given that more than 800 patients have been treated with Elevidys and the overall risk profile remains favorable, I'm confident that SRPT will recover in the coming weeks.
Given the recent FDA approval expansion for Sarepta's Elevidys and the projected revenue growth in the gene therapy market, I believe that SRPT is poi...
Read
More
Given the recent FDA approval expansion for Sarepta's Elevidys and the projected revenue growth in the gene therapy market, I believe that SRPT is poised for significant price appreciation as its market potential continues to expand, making it a strong long-term investment opportunity.
This idea is based on unusual options activity + it's important to note that this is a thinly traded name so consider playing shares instead of option...
Read
More
This idea is based on unusual options activity + it's important to note that this is a thinly traded name so consider playing shares instead of options if you want to play. As long as 136.25 holds I like this one for a move into 142 ahead; BUT if it fails to hold support then this idea fails.